Clinical trials: Cardiac Failure Acute
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
Acute Heart Failure, Heart Failure
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital…
- Trial name
- NCT04363697
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 2,401 people
- Sponsor
- The TIMI Study Group
Acute Decompensated Heart Failure
Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics
The purpose of this research study is to compare the effects (good and bad) of ultrafiltration treatment with standard intravenous (in your vein) diuretic therapy (furosemide, torsemide, bumetanide) on your heart function and…
- Trial name
- NCT01457053
- Testing
- Loop diuretics (furosemide, torsemide, bumetanide), Ultrafiltration
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Cincinnati
Acute Heart Failure, Decompensated Heart Failure
Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study
To determine if a strategy of early discharge using a novel subcutaneous delivery system for parenteral furosemide can improve clinical outcomes within 30 days of randomization (days alive and outside the hospital) compared to…
- Trial name
- SUBQ-HF (NCT03170219)
- Testing
- subcutaneous furosemide and sc2wear device
- Where
- 16 sites in United States
- Volunteers
- 11 people
- Sponsor
- Adrian Hernandez
Acute Decompensated Heart Failure
Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure
The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure.
- Trial name
- NCT04318093
- Testing
- BMS-986259
- Where
- 18 sites in Argentina, Czechia and 4 more
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure
Splanchnic Nerve Anesthesia in Heart Failure
Patients admitted for acute heart failure and undergoing right heart catheterization will be enrolled in this study. Subjects will undergo catheterization of the heart to obtain central cardiac pressure and other cardiac…
- Trial name
- NCT02669407
- Testing
- splanchnic nerve anesthesia with a local anesthetic, regional nerve block with a local anesthetic (Lidocaine)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Duke University
Heart Failure, Cardiac Failure
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment
The purpose of the research is to determine if patients have fewer Heart Failure (HF) events after receiving Aquapheresis (AQ) therapy compared to intravenous (IV) diuretics up to 90 days of discharge from the hospital.
- Conditions
- Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
- Trial name
- AVOID-HF (NCT01474200)
- Testing
- Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD)
- Where
- 38 sites in United States
- Volunteers
- 224 people
- Sponsor
- Nuwellis, Inc.
Acute Decompensated Heart Failure, Acute Kidney Injury
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
AKINESIS is a clinical study to assess the utility of blood and urine NGAL tests in predicting worsening kidney function in patients who present with acute heart failure (AHF) and who are treated with diuretics.
- Trial name
- AKINESIS (NCT01291836)
- Where
- 13 sites in United States, Greece and 5 more
- Volunteers
- 930 people
- Sponsor
- Alere San Diego
Influenza, Pneumonia
Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age.
- Conditions
- Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction
- Trial name
- NCT03694392
- Testing
- Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
- Where
- United States
- Volunteers
- 2,776,278 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Acute Myocardial Infarction, Pacing Therapy
Post-Myocardial Infarction Remodeling Prevention Therapy
The purpose of this study is to demonstrate the feasibility of pacing as a therapy to prevent adverse remodeling of the myocardium following an acute myocardial infarction (MI) in patients at highest risk for adverse myocardial…
- Conditions
- Acute Myocardial Infarction, Pacing Therapy, Cardiac Remodeling, Heart Failure
- Trial name
- PRomPT (NCT01213251)
- Testing
- Single Site Pacing, Dual Site Pacing
- Where
- 26 sites in United States, Denmark and 5 more
- Volunteers
- 129 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Myocardial Infarction
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
- Trial name
- NCT00414609
- Testing
- Aliskiren
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 820 people
- Sponsor
- Novartis
Acute Heart Failure (AHF)
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard…
- Trial name
- RELAX-AHF-EU (NCT02064868)
- Testing
- Serelaxin, Standard of Care
- Where
- 357 sites in Austria, Belgium and 23 more
- Volunteers
- 2,666 people
- Sponsor
- Novartis Pharmaceuticals
Acute Decompensated Heart Failure
A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients
REHAB-HF: A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients, is a multicenter, randomized, attention-controlled, single-blind trial designed to examine the hypothesis that, in addition to standard care, a…
- Trial name
- REHAB-HF (NCT02196038)
- Testing
- multi-domain rehabilitation intervention, Attention Control
- Where
- 3 sites in United States
- Volunteers
- 349 people
- Sponsor
- Wake Forest University Health Sciences
Heart Failure, Asymptomatic Systolic Dysfunction
Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function
The following are done for screening procedures to determine if patients are eligible for this study: blood count, kidney and liver blood tests. Patients will complete a 6-minute walk test.
- Trial name
- NCT00405639
- Testing
- Nesiritide
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Heart Failure
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Heart failure is a disorder in which the heart does not pump blood adequately. This can lead to several serious problems, including reduced blood flow throughout the body, congestion of blood in the veins and lungs, and fluid…
- Trial name
- NCT00577135
- Testing
- Furosemide-Q12 hour bolus, Furosemide-Continuous Infusion, Furosemide-Low Intensification
- Where
- 9 sites in United States, Canada
- Volunteers
- 308 people
- Sponsor
- Duke University